realizing the potential of cdk 4/6 inhibitor therapy in breast cancer: real-world data and evidence
Published 3 years ago • 387 plays • Length 1:02:43Download video MP4
Download video MP3
Similar videos
-
1:09:24
raising the bar in hr /her2- early breast cancer: cdk4 and 6 inhibitors
-
17:54
expert perspectives: cdk 4/6 inhibitors for er breast cancer: current data and clinical use
-
1:17:18
changing standards of care for use of cdk4 and 6 inhibitors in the treatment of breast cancer
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
21:11
current clinical data for cdk 4/6 inhibitors in breast cancer
-
10:02
expert perspectives: cdk 4/6 inhibitors for er breast cancer: emerging data and future implications
-
3:33
cdk 4/6 inhibitors in metastatic breast cancer
-
13:05
expert perspectives: cdk 4/6 inhibitor therapy for er metastatic breast cancer
-
5:16
the clinical potential of cdk4/6 inhibitors
-
7:58
cdk 4/6 inhibitors: how are they used in metastatic breast cancer treatment?
-
1:51
reflecting on the use of cdk4/6 inhibitors in hr breast cancer
-
5:13
evidence-based use of cdk 4/6 inhibitors in breast cancer
-
4:35
hr breast cancer: differences between cdk4/6 inhibitors
-
29:09
interactive case: choosing and using cdk4/6 inhibitors in breast cancer - first-line therapy
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
58:22
adjuvant cdk4 and 6 inhibition to prevent recurrences in high-risk hr /her2- early breast cancer
-
9:18
clinical experience: cdk4/6 inhibitors in breast cancer
-
9:42
expert perspectives: rationale for cdk 4/6 inhibition in breast cancer
-
8:42
hr mbc: treatment after progression on cdk4/6 inhibition